Fulcrum Therapeutics Gross Profit Over Time
| FULC Stock | USD 3.44 0.19 5.85% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Fulcrum Therapeutics Performance and Fulcrum Therapeutics Correlation. Fulcrum |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 1.317 | Quarterly Revenue Growth 89.909 | Return On Assets (0.07) | Return On Equity (0.07) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Gross Profit Analysis
Compare Fulcrum Therapeutics and related stocks such as Capricor Therapeutics, Soleno Therapeutics, and Bio Path Holdings Gross Profit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAPR | 11.5 K | 1.4 M | 195.5 K | 503.2 K | 4.8 M | (10 M) | 3.2 M | 1.4 M | 1.7 M | (4.1 M) | (8.1 M) | (799) | 1.9 M | 24.1 M | 25.3 M |
| SLNO | 3 M | 3 M | 3 M | 3 M | 0.0 | 34.9 K | (58.5 K) | (1.6 B) | 0.0 | (2.3 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2 M) | (2.1 M) |
| BPTH | 23.9 K | 0.0 | 0.0 | 0.0 | 0.0 | (201.8 K) | 13 K | 37 K | (426 K) | (230 K) | (151 K) | (161 K) | (178 K) | (160.2 K) | (152.2 K) |
| MBRX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (6.2 K) | (18 K) | (68 K) | (185 K) | (285 K) | (260 K) | (222 K) | (127 K) | (133.3 K) |
| CRNX | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (7.2 M) | 2.4 M | 1.2 M | 71 K | 1.1 M | 4.7 M | 4 M | 4.2 M |
| ASMB | 0.0 | 0.0 | 0.0 | 0.0 | (24 M) | (65 K) | (80.3 K) | (35.2 M) | (57.9 M) | 16 M | 79 M | 5.8 M | (498 K) | (41.7 M) | (39.7 M) |
| TIL | (20 K) | (20 K) | (20 K) | (20 K) | (20 K) | (20 K) | (20 K) | (20 K) | (20 K) | (20 K) | 138 K | (2.8 M) | (6 M) | (4.8 M) | (4.5 M) |
| CTMX | 888 K | 888 K | 888 K | 888 K | 5.1 M | 7.7 M | 15 M | 71.6 M | 59.5 M | 57.5 M | 100.4 M | 69.6 M | 53.2 M | 99 M | 53.9 M |
| ACHL | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (778 K) | (3.3 M) | (3.7 M) | (4.7 M) | (4.5 M) |
Fulcrum Therapeutics and related stocks such as Capricor Therapeutics, Soleno Therapeutics, and Bio Path Holdings Gross Profit description
Gross profit is a required income statement account that reflects total revenue of Fulcrum Therapeutics minus its cost of goods sold. It is profit before Fulcrum Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.My Equities
My Current Equities and Potential Positions
| Fulcrum Therapeutics | FULC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.44
Check out Fulcrum Therapeutics Performance and Fulcrum Therapeutics Correlation. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Fulcrum Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.